Clinical Trials

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Not yet recruiting

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

640 enrolled

Gynecologic

Endometrial Neoplasms

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

765 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04527991 2025-08-03

TROPiCS-04

Phase 3 Completed

712 enrolled

Genitourinary

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT05552001 2025-06-11

ISIdE

96 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05089734 2025-05-23

EVOKE-01

603 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06431633 2025-04-10

ARIAN

543 enrolled 25 charts 1 FDA

129 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed